Sarah Cannon Research Institute(SCRI) shared on LinkedIn:
“Progress continues in lung cancer care, with new findings from Sarah Cannon Research Institute supporting advances in precision medicine.
Dr. Melissa Johnson, Chief Scientific Officer and Director of Lung Cancer Research at Sarah Cannon Research Institute, discusses the LIBRETTO-432 findings and their potential implications for patients with RET fusion-positive non-small cell lung cancer.
Watch the Lung Cancers Today interview and learn more.”
LIBRETTO-432 Trial at ASCO 2026 Plenary Session: Adjuvant Selpercatinib in RET Fusion-Positive NSCLC
